Influence of CYP2C19 Genetic Polymorphisms and Helicobacter pylori Infection on Efficacy of Omeprazole Treatment in Patients With Nonvariceal Upper Gastrointestinal Tract Bleeding: a Prospective, Randomized Clinical Study

Trial Profile

Influence of CYP2C19 Genetic Polymorphisms and Helicobacter pylori Infection on Efficacy of Omeprazole Treatment in Patients With Nonvariceal Upper Gastrointestinal Tract Bleeding: a Prospective, Randomized Clinical Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs Omeprazole (Primary)
  • Indications Gastrointestinal haemorrhage
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 01 Jul 2013 New trial record
    • 18 May 2013 Results presented at the Digestive Disease Week 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top